Denali Therapeutics Ownership | Who Owns Denali Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Denali Therapeutics Ownership Summary


Denali Therapeutics is owned by 69.52% institutional investors, 9.13% insiders, and 21.35% retail investors. Blackrock is the largest institutional shareholder, holding 8.82% of DNLI shares. Scottish Mortgage Ord is the top mutual fund, with 4.44% of its assets in Denali Therapeutics shares.

DNLI Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockDenali Therapeutics69.52%9.13%21.35%
SectorHealthcare Stocks 35.56%12.08%52.36%
IndustryBiotech Stocks 35.43%12.01%52.56%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock13.17M8.82%$305.91M
Vanguard group13.06M7.57%$215.59M
Blackrock funding, inc. /de14.03M7.52%$360.76M
Baillie gifford11.96M6.41%$307.62M
T. rowe price investment management8.52M4.86%$163.57M
State street7.05M3.78%$181.31M
Temasek (private)7.01M3.76%$180.37M
Vanguard capital management6.28M3.36%$161.41M
Goldman sachs group4.41M2.51%$84.62M
Fmr4.54M2.43%$116.66M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Crestline management, lp2.21M91.74%$42.45M
Foresite capital management vi1.21M5.05%$23.23M
Casdin capital1.84M2.68%$35.33M
Stempoint capital lp426.56K1.59%$8.19M
Cercano management625.00K1.55%$16.07M
Dafna capital management318.50K1.39%$6.12M
Boxer capital management250.00K1.16%$3.63M
Privium fund management b.v.229.86K1.09%$5.91M
Yiheng capital management469.98K1.01%$6.82M
Vestal point capital, lp1.77M0.95%$34.05M

Top Buyers

HolderShares% AssetsChange
Norges bank2.82M0.01%2.82M
Vestal point capital, lp1.77M0.95%1.31M
T. rowe price investment management8.52M0.11%1.27M
Alyeska investment group1.94M0.11%1.08M
Vanguard group13.06M0.00%1.06M

Top Sellers

HolderShares% AssetsChange
Lynx1 capital management lp11.66K0.06%-1.87M
Point72 asset management---1.70M
Price t rowe associates inc /md/2.46M0.01%-1.45M
Flagship pioneering---1.36M
Ubs asset management americas3.16M0.01%-1.27M

New Positions

HolderShares% AssetsChangeValue
Norges bank2.82M0.01%2.82M$72.65M
Braidwell lp296.32K0.19%296.32K$5.69M
Axa investment managers294.73K0.01%294.73K$4.28M
Schonfeld strategic advisors226.20K0.02%226.20K$3.28M
Balyasny asset management195.11K0.00%195.11K$3.75M

Sold Out

HolderChange
Truvestments capital-1.00
Curio wealth-1.00
Vermillion wealth management-1.00
Toronto dominion bank-2.00
Global financial private client-5.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 2026235-7.11%121,971,228-19.30%690.90%136-47-33.80%
Dec 31, 202569-71.60%34,419,053-74.60%190.32%37-70.63%15-76.92%
Sep 30, 202584-62.83%32,008,693-75.36%180.33%39-67.77%28-56.25%
Jun 30, 20252304.07%137,233,4273.48%801.33%12214.02%66-17.50%
Mar 31, 2025220-3.51%132,840,2763.83%771.36%108-14.96%8035.59%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Scottish Mortgage Ord7.04M4.44%-
T. Rowe Price Capital Appreciation4.97M3.13%4.97M
Vanguard Health Care Inv4.40M3.03%-5.17M
Vanguard Total Stock Mkt Idx Inv4.29M2.70%20.55K
Vanguard Morn Total Stk Mkt Idx Investor4.29M2.70%20.55K
iShares Russell 2000 ETF3.75M2.36%-66.62K
Vanguard US Total Market Shares ETF3.33M2.29%-161.11K
State Street® SPDR® S&P® Biotech ETF3.41M2.15%7.84K
Vanguard Small Cap Index3.09M1.95%-15.08K
Baillie Gifford US Equity Growth3.04M1.91%-

Recent Insider Transactions


DateNameRoleActivityValue
Aug 11, 2026Schuth Alexander O. COFO and SecretarySell$71.62K
Jan 06, 2026Watts Ryan J. President and CEOSell$580.77K
Jan 06, 2026Schuth Alexander O. COFO and SecretarySell$284.10K
Dec 11, 2025BAKER BROS. ADVISORS LP-Buy$20.95K
Dec 11, 2025BAKER BROS. ADVISORS LP-Buy$1.91K

Insider Transactions Trends


DateBuySell
2026 Q3-1
2026 Q2--
2026 Q1-2
2025 Q42-
2025 Q3-4

DNLI Ownership FAQ


Who Owns Denali Therapeutics?

Denali Therapeutics shareholders are primarily institutional investors at 69.52%, followed by 9.13% insiders and 21.35% retail investors. The average institutional ownership in Denali Therapeutics's industry, Biotech Stocks , is 35.43%, which Denali Therapeutics exceeds.

Who owns the most shares of Denali Therapeutics?

Denali Therapeutics’s largest shareholders are Blackrock (13.17M shares, 8.82%), Vanguard group (13.06M shares, 7.57%), and Blackrock funding, inc. /de (14.03M shares, 7.52%). Together, they hold 23.91% of Denali Therapeutics’s total shares outstanding.

Does Blackrock own Denali Therapeutics?

Yes, BlackRock owns 8.82% of Denali Therapeutics, totaling 13.17M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 305.91M$. In the last quarter, BlackRock increased its holdings by 974.71K shares, a 7.99% change.

Who is Denali Therapeutics’s biggest shareholder by percentage of total assets invested?

Crestline management, lp is Denali Therapeutics’s biggest shareholder by percentage of total assets invested, with 91.74% of its assets in 2.21M Denali Therapeutics shares, valued at 42.45M$.

Who is the top mutual fund holder of Denali Therapeutics shares?

Scottish Mortgage Ord is the top mutual fund holder of Denali Therapeutics shares, with 4.44% of its total shares outstanding invested in 7.04M Denali Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools